That rate of growth should be attainable with Vertex lining up new reimbursement deals for its drugs in key markets and especially with the prospects of Trikafta soon winning European regulatory approval.The biotech picked up additional approvals for other rare indications in subsequent years, including atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).